Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Kevin Kotler’s Broadfin Capital Reveals New Stake in Dipexium Pharmaceuticals (DPRX)

A new filing with the SEC, Kevin Kotler and his hedge fund Broadfin Capital revealed new stake in Dipexium Pharmaceuticals, Inc (NASDAQ:DPRX). In Dipexium Pharmaceuticals, Kevin Kotler currently owns a total of 475,000 shares, which make the holding equal to 5.85% of the common stock.

Kevin Kotler

Dipexium Pharmaceuticals, Inc (NASDAQ:DPRX), founded in 2010, develops and commercializes Locilex, a peptide topical antibiotic, to treat mild or moderate acute bacterial skin and skin structure infections in superficial wounds. Formerly, the emerging biotechnology company was known as Dipexium Pharmaceuticals, LLC.

Last month, the company closed its initial public offering of approximately 3.2 million shares at an offer price of $12.0 per share. Dipexium raised net proceeds of approximately $35.1 million and the biotechnology company plans to use the net proceeds to further develop its antibiotic, Locilex. A couple of days ago, the Oppenheimer initiated coverage on Dipexium with an ‘outperform’ rating at a target price of $27.0 per share.

In February, Dipexium Pharmaceuticals, Inc (NASDAQ:DPRX) entered into a partnership with RRD International LLC, a provider of product development and expert-level support services to biopharmaceutical companies and investors, to develop Locilex.

Broadfin Capital is located in New York City. The fund has an equity portfolio of $758.2 million, concentrated in the Healthcare sector. Kevin Kotler, the founder of the fund has worked with The Galleon Group, ABN AMRO, and ING Barings.

Broadfin Capital has been active in the recent couple of months, reporting new stakes in several companies. Last month, the fund initiated position in Pernix Therapeutics (NASDAQ:PTX), with 3.5 million shares. In January, the fund disclosed holding a 6.9% stake in Retrophin Inc (NASDAQ:RTRX), which contains 1.61 million shares.

According to the fund’s latest 13F, top holdings of Broadfin Capital, as at the end of last year, were Depomed Inc (NASDAQ:DEPO), with a stake valued in excess of $50.2 million, followed by Lannett Company, Inc. (NYSE:LCI), of which it held around 1.3 million shares worth $44.4 million, and Angiodynamics Inc (NASDAQ:ANGO), in which it owned 2.5 million shares valued at more than $42.8 million.

Disclosure: none

Recommended Reading:

Kevin Kotler’s Broadfin Capital’s and MELA Sciences (MELA)

Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO

Broadfin Capital Ups Position in Rigel Pharmaceuticals, Inc. (RIGL)

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!